

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2021/222479 A9

(43) International Publication Date
04 November 2021 (04.11.2021)

(51) International Patent Classification:
C12N 5/0783 (2010.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2021/029762

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:
28 April 2021 (28.04.2021)

Published:

— with international search report (Art. 21(3))

(25) Filing Language: English

(26) Publication Language: English

(48) Date of publication of this corrected version:

11 August 2022 (11.08.2022)

(30) Priority Data:
63/016,907 28 April 2020 (28.04.2020) US

(15) Information about Correction:

see Notice of 11 August 2022 (11.08.2022)

(71) Applicant: **LYELL IMMUNOPHARMA, INC.**
[US/US]; 201 Haskins Way, South San Francisco, CA
94080 (US).

(72) Inventors: **VODNALA, Suman Kumar**; 201 Haskins
Way, South San Francisco, CA 94080 (US). **EIL, Robert
Langland**; 201 Haskins Way, South San Francisco, CA
94080 (US). **RESTIFO, Nicholas P.**; 201 Haskins Way,
South San Francisco, CA 94080 (US).

(74) Agent: **KIM, Ji Eun** et al.; STERNE, KESSLER,
GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue,
NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS FOR CULTURING CELLS

(57) Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells, NK cells, and/or TILs) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.



WO 2021/222479 A9